Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Polycyclic aromatic hydrocarbon--DNA adducts in prostate and biochemical recurrence after prostatectomy.

Rybicki BA, Neslund-Dudas C, Bock CH, Rundle A, Savera AT, Yang JJ, Nock NL, Tang D.

Clin Cancer Res. 2008 Feb 1;14(3):750-7. doi: 10.1158/1078-0432.CCR-07-0986.

2.

Polycyclic aromatic hydrocarbon-DNA adducts in prostate cancer.

Rybicki BA, Rundle A, Savera AT, Sankey SS, Tang D.

Cancer Res. 2004 Dec 15;64(24):8854-9.

3.

Elevated polycyclic aromatic hydrocarbon-DNA adducts in benign prostate and risk of prostate cancer in African Americans.

Tang D, Kryvenko ON, Wang Y, Jankowski M, Trudeau S, Rundle A, Rybicki BA.

Carcinogenesis. 2013 Jan;34(1):113-20. doi: 10.1093/carcin/bgs326. Epub 2012 Oct 12.

4.

Associations between smoking, polymorphisms in polycyclic aromatic hydrocarbon (PAH) metabolism and conjugation genes and PAH-DNA adducts in prostate tumors differ by race.

Nock NL, Tang D, Rundle A, Neslund-Dudas C, Savera AT, Bock CH, Monaghan KG, Koprowski A, Mitrache N, Yang JJ, Rybicki BA.

Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1236-45.

5.

The relationship between genetic damage from polycyclic aromatic hydrocarbons in breast tissue and breast cancer.

Rundle A, Tang D, Hibshoosh H, Estabrook A, Schnabel F, Cao W, Grumet S, Perera FP.

Carcinogenesis. 2000 Jul;21(7):1281-9.

PMID:
10874004
6.

A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.

Cullen J, Rosner IL, Brand TC, Zhang N, Tsiatis AC, Moncur J, Ali A, Chen Y, Knezevic D, Maddala T, Lawrence HJ, Febbo PG, Srivastava S, Sesterhenn IA, McLeod DG.

Eur Urol. 2015 Jul;68(1):123-31. doi: 10.1016/j.eururo.2014.11.030. Epub 2014 Nov 29.

7.

Polymorphisms in glutathione S-transferase genes increase risk of prostate cancer biochemical recurrence differentially by ethnicity and disease severity.

Nock NL, Bock C, Neslund-Dudas C, Beebe-Dimmer J, Rundle A, Tang D, Jankowski M, Rybicki BA.

Cancer Causes Control. 2009 Dec;20(10):1915-26. doi: 10.1007/s10552-009-9385-0.

8.

Racial differences in clinical and pathological associations with PhIP-DNA adducts in prostate.

Tang D, Liu JJ, Bock CH, Neslund-Dudas C, Rundle A, Savera AT, Yang JJ, Nock NL, Rybicki BA.

Int J Cancer. 2007 Sep 15;121(6):1319-24.

9.

Quantification of phase I/II metabolizing enzyme gene expression and polycyclic aromatic hydrocarbon-DNA adduct levels in human prostate.

John K, Ragavan N, Pratt MM, Singh PB, Al-Buheissi S, Matanhelia SS, Phillips DH, Poirier MC, Martin FL.

Prostate. 2009 Apr 1;69(5):505-19. doi: 10.1002/pros.20898.

10.

Polycyclic aromatic hydrocarbon-DNA adducts in liver tissues of hepatocellular carcinoma patients and controls.

Chen SY, Wang LY, Lunn RM, Tsai WY, Lee PH, Lee CS, Ahsan H, Zhang YJ, Chen CJ, Santella RM.

Int J Cancer. 2002 May 1;99(1):14-21.

11.

Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.

Fossati N, Karnes RJ, Cozzarini C, Fiorino C, Gandaglia G, Joniau S, Boorjian SA, Goldner G, Hinkelbein W, Haustermans K, Tombal B, Shariat S, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T, Briganti A.

Eur Urol. 2016 Apr;69(4):728-33. doi: 10.1016/j.eururo.2015.10.009. Epub 2015 Oct 21.

PMID:
26497924
12.

Short (≤ 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy.

Shikanov S, Marchetti P, Desai V, Razmaria A, Antic T, Al-Ahmadie H, Zagaja G, Eggener S, Brendler C, Shalhav A.

BJU Int. 2013 Apr;111(4):559-63. doi: 10.1111/j.1464-410X.2012.11340.x. Epub 2012 Jul 3.

13.

Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer.

Johnson SB, Hamstra DA, Jackson WC, Zhou J, Foster B, Foster C, Song Y, Li D, Palapattu GS, Kunju L, Mehra R, Sandler H, Feng FY.

Int J Radiat Oncol Biol Phys. 2013 Oct 1;87(2):275-81. doi: 10.1016/j.ijrobp.2013.05.043. Epub 2013 Jul 23.

PMID:
23886418
14.

Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.

Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Freedland SJ.

BJU Int. 2014 Nov;114(5):661-6. doi: 10.1111/bju.12720. Epub 2014 May 8.

15.

Risk-adjusted hazard rates of biochemical recurrence for prostate cancer patients after radical prostatectomy.

Walz J, Chun FK, Klein EA, Reuther A, Graefen M, Huland H, Karakiewicz PI.

Eur Urol. 2009 Feb;55(2):412-19. doi: 10.1016/j.eururo.2008.11.005. Epub 2008 Nov 21.

PMID:
19027223
16.

Immunoperoxidase detection of polycyclic aromatic hydrocarbon-DNA adducts in mouth floor and buccal mucosa cells of smokers and nonsmokers.

Besaratinia A, Van Straaten HW, Godschalk RW, Van Zandwijk N, Balm AJ, Kleinjans JC, Van Schooten FJ.

Environ Mol Mutagen. 2000;36(2):127-33. Erratum in: Environ Mol Mutagen. 2005 Aug;46(2):140. Besarati Nia, A [corrected to Besaratinia, A].

PMID:
11013411
17.

Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.

Rosenbaum E, Hoque MO, Cohen Y, Zahurak M, Eisenberger MA, Epstein JI, Partin AW, Sidransky D.

Clin Cancer Res. 2005 Dec 1;11(23):8321-5.

18.

Genetic variants in microRNAs and microRNA target sites predict biochemical recurrence after radical prostatectomy in localized prostate cancer.

Huang SP, Lévesque E, Guillemette C, Yu CC, Huang CY, Lin VC, Chung IC, Chen LC, Laverdière I, Lacombe L, Fradet Y, Chang TY, Lee HZ, Juang SH, Bao BY.

Int J Cancer. 2014 Dec 1;135(11):2661-7. doi: 10.1002/ijc.28904. Epub 2014 Apr 22.

19.

A single nucleotide polymorphism in ADIPOQ predicts biochemical recurrence after radical prostatectomy in localized prostate cancer.

Gu C, Qu Y, Zhang G, Sun L, Zhu Y, Ye D.

Oncotarget. 2015 Oct 13;6(31):32205-11. doi: 10.18632/oncotarget.4980.

20.

BMI is associated with larger index tumors and worse outcome after radical prostatectomy.

Hayashi N, Matsushima M, Kido M, Naruoka T, Furuta A, Furuta N, Takahashi H, Egawa S.

Prostate Cancer Prostatic Dis. 2014 Sep;17(3):233-7. doi: 10.1038/pcan.2014.15. Epub 2014 May 20.

PMID:
24841331

Supplemental Content

Support Center